In a double-blind, placebo-controlled, within-subject crossover study, psilocybin microdosing (a sub-hallucinogenic dose taken every third day) did not alter emotion processing, symptoms of anxiety or depression, or self-reported interoceptive awareness compared with placebo. Exploratory analyses showed that symptoms of depression and stress were significantly reduced in the first block compared with baseline, but participants broke blind in the second block, and there was no effect of expectations. The authors call for further research in a substance-naïve population with clinical-range anxiety and depressive symptoms to substantiate potential beneficial effects.
People who take small, non-hallucinogenic doses of psilocybin (microdosing) report feeling more awe when watching videos of funny animals and moving objects compared to when they take a placebo. However, about two-thirds of participants correctly guessed whether they had received psilocybin or placebo, suggesting that expectancy effects—rather than the drug itself—may explain the subjective benefits of microdosing. The study used a double-blind, placebo-controlled crossover design with a microdosing workshop and lab visits over several weeks.